Table 2

Baseline results of autoantibody assays in the antiphospholipid (aPL) carriers and their thrombosis rate

AutoantibodiesPrevalenceThrombotic events
NoYes
IgG aCL medium/high titres101/258 (39.1%)95/244 (38.9%)6/14 (42.9%)
IgM aCL medium/high titres74/258 (28.7%)69/244 (28.3%)5/14 (35.7%)
IgG anti-β2GPI medium/high titres104/258 (40.3%)99/244 (40.6%)5/14 (35.7%)
IgM anti-β2GPI medium/high titres79/258 (30.6%)74/244 (30.3%)5/14 (35.7%)
Lupus anticoagulants130/258 (50.4%)119/244 (48.8%)11/14 (78.6%)*
aPL antibody category I130/258 (50.4%)121/244 (49.6%)9/14 (64.3%)
aPL antibody category II128/258 (49.6%)123/244 (50.4%)5/14 (35.7%)
Antinuclear antibodies163/258 (63.2%)154/244 (63.1%)9/14 (64.3%)
Anti-double strand DNA antibodies33/255 (26.4%)31/241 (12.9%)2/14 (14.3%)
Anti-extractable nuclear antigen antibodies52/258 (12.9%)48/244 (19.7%)4/14 (28.6%)
  • * Statistically significant (p<0.05).

  • aCL, anticardiolipin antibodies; anti-β2GPI, anti-β2-glycoprotein I antibodies.